Natural history of HCV infection

Bailliere's Best Practice and Research in Clinical Gastroenterology

Volumn 14, Issue 2, 2000, Pages 211-228

  Poynard, Thierry ^c   Ratziu, Vlad ^c   Benhamou, Yves ^c   Opolon, Pierre ^c   Cacoub, Patrice ^a,b   Bedossa, Pierre ^c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c NONE

Author keywords

Activity scoring system; Cryoglobulinaemia; Fibrosis; Hepatitis C; Modelling; Natural history; Non hepatological manifestation

Indexed keywords

ANTINUCLEAR ANTIBODY; CD4 ANTIGEN; CRYOGLOBULIN; SMOOTH MUSCLE ANTIBODY;

AGE; ALCOHOL CONSUMPTION; ARTHROPATHY; DISEASE COURSE; DISEASE DURATION; FATIGUE; GENDER; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CIRRHOSIS; LIVER FIBROSIS; LYMPHOCYTE COUNT; MUSCLE DISEASE; REVIEW; SKIN DISEASE; SYSTEMIC VASCULITIS;

EID: 0034046820     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1053/bega.1999.0071     Document Type: Article

References (124)

1. Weekly Epidemiological Record. 72:1997;341-344.
2. Seeff L B, Buskell-Bales Z, Wright E C. Long-term mortality after transfusion-associated non-A non-B hepatitis. New England Journal of Medicine. 327:1992;1906-1911.
3. Tong M J, el-Ferra N S, Reikes A R, Co R L. Clinical outcomes after transfusion-associated hepatitis C. New England Journal of Medicine. 332:1995;1463-1466.
4. Darby S C, Ewart D W, Giangrande P LF. Mortality from liver cancer and liver disease in haemophilic men and boys given blood products contaminated with hepatitis C. Lancet. 350:1997;1425-1431.
5. El-Serag H B, Mason A. Rising incidence of hepatocellular carcinoma in the United States. New England Journal of Medicine. 34:1999;745-750.
6. Taylor-Robinson S D, Foster G R, Arora S, Hargreaves S, Thomas H C. Increase in primary liver cancer in the UK, 1979-94. Lancet. 350:1997;1142-1143.
7. Deuffic S, Poynard T, Buffat L, Valleron A-J. Trends in primary liver cancer. Lancet. 351:1998;214-215.
8. Deuffic S, Buffat L, Poynard T, Valleron A J. Modeling the hepatitis C virus epidemic in France. Hepatology. 29:1999;1596-1601.
9. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet. 349:1997;825-832.
10. Sobesky R, Mathurin P, Charlotte F. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. Gastroenterology. 116:1999;378-386.
11. Scheuer P J. Classification of chronic viral hepatitis: a need for reassessment. Journal of Hepatology. 13:1991;372-374.
12. Ludwig J. The nomenclature of chronic active hepatitis: an obituary. Gastroenterology. 105:1993;274-278.
13. Desmet V J, Gerber M, Hoofnagle J H, Manns M, Scheuer P J. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 19:1994;1513-1519.
14. Hepatology. 20:1994;15-20.
15. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 24:1996;289-293.
16. Knodell K G, Ishak K G, Black W C. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1:1981;431-435.
17. Wong V S, Wight D G, Palmer C R, Alexander G J. Fibrosis and other histological features in chronic hepatitis C virus infection: a statistical model. Journal of Clinical Pathology. 49:1996;465-469.
18. Poynard T, Bedossa P. Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups. Journal of Viral Hepatology. 4:1997;199-208.
19. Paradis V, Mathurin P, Laurent A. Histological features predictive of liver fibrosis in chronic hepatitis C infection. Journal of Clinical Pathology. 49:1996;998-1004.
20. Yano M, Kumada H, Kage M. The long term pathological evolution of chronic hepatitis C. Hepatology. 23:1996;1334-1340.
21. Poynard T, McHutchison J, Davis G. Impact of interferon alfa-2b and ribavirin on the liver fibrosis progression in patients with chronic hepatitis C. Hepatology. 28:1998;497A.
22. Datz C, Cramp M, Haas T. The natural course of hepatitis C virus infection 18 years after an epidemic outbreak of non-A, non-B hepatitis in a plasmapheresis centre. Gut. 44:1999;563-567.
23. Czaja A, Carpenter H, Santrach P, Moore B. Host and disease specific factors affecting steatosis in chronic hepatitis C. Journal of Hepatology. 29:1998;198-206.
24. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. New England Journal of Medicine. 340:1999;1228-1233.
25. Pol S, Fontaine H, Carnot F. Predictive factors for develoopment of cirrhosis in parenterally acquired chronic hepatitis C: a comparison between immunocompetent and immunocompromised patients. Journal of Hepatology. 29:1998;12-19.
26. Pessione F, Degos F, Marcellin P. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology. 27:1998;1717-1722.
27. Khan M H, Thomas L, Byth K. How much does alcohol contribute to the variability of hepatic fibrosis in chronic hepatitis C? Journal of Gastroenterology and Hepatology. 13:1998;419-426.
28. Wiley T E, McCarthy M, Breidi L, McCarthy M, Layden T J. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology. 28:1998;805-809.
29. Garcia-Samaniego J, Soriano V, Castilla J. Influence of hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C. American Journal of Gastroenterology. 92:1997;1130-1134.
30. Benhamou Y, Bochet M, Di Martino V. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology. 30:1999;1054-1058.
31. Di Martino V, Rufat P, Renard P. Detrimental influence of HIV infection on the outcome of chronic hepatitis C: a long-term follow-up cohort study in intravenous drug abusers. Hepatology. 24:1996;382A.
32. Goodson J D, Taylor P A, Campion E W. The clinical course of acute hepatitis in the elderly patient. Archives of Internal Medicine. 142:1982;1485-1488.
33. Wynne H A, Cope L H, Mutch E. The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology. 9:1989;297-301.
34. Nagel J E, Chrest J J, Adler H H. Enumeration of T lymphocytes by monoclonal antibodies in young age and aged humans. Journal of Immunology. 127:1981;2086-2088.
35. Makinodan T, Kay M MB. Age influence on the immune system. Advances in Immunology. 29:1980;287-291.
36. Poynter M E, Daynes R A. Peroxysome proliferator-activated receptor α activation modulates cellular redox status, represses nuclear factor-kB signaling, and reduces inflammatory cytokine production in aging. Journal of Biological Chemistry. 273:1998;32833-32841.
37. Bissell D M. Sex and hepatic fibrosis. Hepatology. 29:1999;988-989.
38. Yasuda M, Shimizu I, Shiba M, Ito S. Suppressive effects of estradiol on dimethylnitrosamine-induced fibrosis of the liver in rats. Hepatology. 29:1999;719-727.
39. Ashcroft G S, Dodsworth J, van Boxtel E. Estrogen accelerates cutaneous wound healing associated with an increase in TGF-beta1 levels. Nature Medicine. 3:1997;1209-1215.
40. Wang Y J, Wang S S, Bickel M. Two novel antifibrotics, HOE 077 and Safironil, modulate stellate cell activation in rat liver injury: differential effects in males and females. American Journal of Pathology. 152:1998;279-287.
41. Bentzen S M, Skoczylas J Z, Overgaard M, Overgaard J. Radiotherapy-related lung fibrosis enhanced by tamoxifen. Journal of the National Cancer Institute. 88:1996;918-922.
42. De Moliner L, Pontisson P, De Salvo G L. Serum and liver HCV RNA levels in patients with chronic hepatitis C: correlation with clinical and histological features. Gut. 42:1998;856-860.
43. Roffi L, Ricci A, Ogliari C J. HCV genotypes in Northern Italy: a survey of 1368 histologically proven chronic hepatitis C patients. Journal of Hepatology. 29:1998;701-706.
44. Leone F, Zylberberg H, Squadrito G. Hepatitis C virus (HCV) hypervariable region 1 complexity does not correlate with severity of liver disease, HCV type, viral load or duration of infection. Journal of Hepatology. 29:1998;689-694.
45. Lopez-Labrador F X, Ampurdanes S, Gimenez-Barcons M. Relationship of the genomic complexity of hepatitis C virus with liver disease severity and response to interferon in patients with chronic HCV genotype 1b interferon. Hepatology. 29:1999;897-903.
46. Pontisso P, Bellati G, Brunetto M. Hepatitis C virus RNA profiles in chronically infected individuals: do they relate to disease activity? Hepatology. 29:1999;585-589.
47. Napoli J, Bishop A, McGuiness P H. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology. 24:1996;759-765.
48. Cramp M E, Carucci P, Underhill J. Association between HLA class II genotype and spontaneous clearance of hepatitis C viraemia. Journal of Hepatology. 29:1998;207-213.
49. Minton E J, Smillie D, Neal K R. Association between MHC class II alleles and clearance of circulating hepatitis C virus. Members of the Trent Hepatitis C Virus Study Group. Journal of Infectious Diseases. 178:1998;39-44.
50. Russo M, Grimm I S. HCV and C282Y: a sinister synergism? Gastroenterology. 116:1999;494-495.
51. Njapoum C, Pessione F, Duchatelle V. La fibrose hépatique est augmentée chez les fumeurs au cours de l'hépatite chronique C. Gastroenterologie Clinique et Biologique. 23:1999;137A.
52. Mathurin P, Moussalli J, Cadranel J F. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology. 27:1998;868-872.
53. Berenguer M, Ferrell L, Kim M. Fibrosis progression in recurrent HCV disease: differences between the US and Europe. Journal of Hepatology. 2000.
54. Sharara A I, Hunt C M, Hamilton J D. Hepatitis C. Annals of Internal Medicine. 125:1996;658-668.
55. Gumber S C, Chopra S C. Hepatitis C: a multifaced disease. Review of extrahepatic manifestations. Annals of Internal Medicine. 123:1995;615-620.
56. Pawlotsky J M, Ben Yahia M, Andre C. Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology. 19:1994;841-848.
57. Clifford B D, Donahue D, Smith L. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology. 21:1995;613-619.
58. Richardet J P, Lons T, Johanet C. Prévalence et caractéristiques des anticorps anti-tissus au cours des hépatites chroniques dues au virus de l'hépatite C. Gastroenterologie Clinique et Biologique. 18:1994;819-823.
59. Cacoub P, Poynard T, Ghillani P. Extrahepatic manifestations in patients with chronic hepatitis C. Arthritis and Rheumatism. 42:1999;2204-2212.
60. Seigel L B, Cohn L, Nashel D. Rheumatic manifestations of hepatitis C infection. Seminars in Arthritis and Rheumatism. 23:1993;149-154.
61. Perrot S, Job-Deslandre C, Peuchal X, Menkes C. Hepatitis C virus related polyarthritis: 11 cases. Arthritis and Rheumatism. 37:1994;S234.
62. Ueno Y, Kinoshita R, Kishimoto I, Okamoto S. Polyarthritis associated with hepatitis C virus infection. British Journal of Rheumatology. 33:1994;289-291.
63. Borque L, Elena A, Maside C, Rus A, Del Cura J. Rheumatoid arthritis and hepatitis C virus antibodies. Clinical and Experimental Rheumatology. 9:1991;617-619.
64. Lovy M R, Sarkebaum G, Uberoi S. Hepatitis C infection presenting with rheumatic manifestations. A mimic of rhetumatoid arthritis. Journal of Rheumatology. 23:1996;979-983.
65. Ripault M P, Borderie C, Dumas P. Neuropathies périphériques et hépatite virale C: une association fréquente? Gastroenterologie Clinique et Biologique. 22:1998;891-896.
66. Apartis E, Léger J M, Musset L. Peripheral neuropathy associated with essential mixed cryoglobulinemia: a role for hepatitis C virus infection? Journal of Neurology Neurosurgery and Psychiatry. 60:1996;661-666.
67. Ferri C, La Civita L, Cirafisi C. Peripheral neuropathy in mixed cryoglobulinemia: clinical and electrophysiologic investigations. Journal of Rheumatology. 19:1992;889-895.
68. Pawlotsky J M, Roudot-Thoraval F, Simmonds P. Extrahepatic immunologic manifestations in chronic hepatitis C and hepatitis C virus serotypes. Annals of Internal Medicine. 122:1995;169-173.
69. Dupin N, Chosidow O, Lunel F. Essential mixed cryoglobulinemia. A comparative study of dermatologic manifestations in patients infected or non infected with hepatitis C virus. Archives of Dermatology. 131:1995;1124-1127.
70. Donada C, Crucitti A, Donadon V. Systemic manifestations and liver disease in patients with chronic hepatitis C and type II or III mixed cryoglobulinemia. Journal of Viral Hepatitis. 5:1998;179-185.
71. D'Alessandro Gondolfo L, Biolcati G, Griso D, Macri A, Topi G. Frequency of viral hepatitis markers in porphyria cutanea tarda. European Journal of Dermatology. 3:1993;180-182.
72. Cribier B, Petiau P, Keller F. Porphyria cutanea tarda and hepatitis C virus infection: a clinical and virological study. Archives of Dermatology. 131:1995;801-804.
73. Fargion S, Piperno A, Cappelini M D. Hepatitis C virus and porphyria cutanea tarda: evidence for a strong association. Hepatology. 16:1992;1322-1326.
74. Herrero C, Vicente A, Bruguera M. Is hepatitis C virus infection a trigger of porphyria cutanea tarda? Lancet. 341:1993;788-789.
75. De Castro M, Sanchez J, Herrera J F. Hepatitis C virus antibodies and liver disease in patients with porphyria cutanea tarda. Hepatology. 17:1993;551-557.
76. Murphy A, Dooley S, Hillary I B, Murphy G M. Hepatitis C virus infection in porphyria cutanea tarda. Lancet. 341:1993;1534-1535.
77. Strötzel U, Köstler E, Koszka C. Low prevalence of hepatitis C virus infection in porphyria cutanea tarda in Germany. Hepatology. 21:1995;1500-1502.
78. Salmon P, Oakley A, Rademaker M, Duffill M. Hepatitis C virus infection and porphyria cutanea tarda in Australia. Archives of Dermatology. 132:1996;91.
79. Lacour J P, Bodokh I, Castanet J, Bekri S, Ortonne J P. Porphyria cutanea tarda and antibodies to hepatitis C virus. British Journal of Dermatology. 128:1993;121-123.
80. Cribier B, Garnier C, Laustriat D, Heid E. Lichen planus and hepatitis C virus infection: an epidemiologic study. Journal of the American Academy of Dermatology. 31:1994;1070-1072.
81. Jubert C, Pawlotsky J M, Pouget F. Lichen planus and hepatitis C virus-related chronic active hepatitis. Archives of Dermatology. 130:1994;73-76.
82. Mokni M, Rybojad M, Puppin D. Lichen planus and hepatitis C virus. Journal of the American Academy of Dermatology. 24:1991;792.
83. Sanchez-Perez J, De Castro M, Buezo G F. Lichen planus and hepatitis C virus: prevalence and clinical presentation of patients with lichen planus and hepatitis C virus infection. British Journal of Dermatology. 134:1996;715-719.
84. Haddad J, Deny P, Munz-Gotheil C. Lymphocytic sialadenitis of Sjögren's syndrome associated with chronic hepatitis C virus liver disease. Lancet. 339:1992;321-323.
85. Mariette X, Zerbib M, Jaccard A. Hepatitis C virus and Sjögren's syndrome. Arthritis and Rheumatism. 36:1993;280-281.
86. Almasio P, Provenzano G, Scimemi M. Hepatitis C virus and Sjögren's syndrome. Lancet. 339:1992;989-990.
87. Jorgensen C, Legouffe M C, Perney P. Sicca syndrome associated with hepatitis C virus infection. Arthritis and Rheumatism. 43:1996;1166-1171.
88. Aceti A, Taliani G, Sorice M, Amendolea M A. Hepatitis C virus and Sjögren's syndrome. Lancet. 339:1992;1425-1426.
89. King P D, McMurray R W, Becherer P R. Sjögren's syndrome without mixed cryoglobulinemia is not associated with hepatitis C virus infection. American Journal of Gastroenterology. 89:1994;1047-1050.
90. Boscagli A, Hatron P Y, Canva-Delcambre V. Syndrome sec et infection par le virus de l'hépatite C: un pseudosyndrome de Gougerot-Sjögren. Revue de Medicine Interne. 17:1996;375-380.
91. Wattiaux M J, Jouan-Flahault C, Youinou P. Association of Gougerot-Sjögren syndrome and viral hepatitis C. Annales de Medicine Interne. 146:1995;247-250.
92. Ferri C, Greco F, Longombardo G. Antibodies to hepatitis C virus in patients with mixed cryoglobulinemia. Arthritis and Rheumatism. 34:1991;1606-1610.
93. Misiani R, Bellavita P, Fenili D. Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Annals of Internal Medicine. 117:1992;573-577.
94. Cacoub P, Musset L, Lunel-Fabiani F. Hepatitis C virus and essential mixed cryoglobulinemia. British Journal of Rheumatology. 32:1993;685-692.
95. Marcellin P, Deschamps V, Martinot-Peignoux M. Cryoglobulinemia with vasculitis associated with hepatitis C virus infection. Gastroenterology. 104:1993;272-277.
96. Cacoub P, Lunel-Fabiani F, Musset L. Mixed cryoglobulinemia and hepatitis C virus. American Journal of Medicine. 96:1994;124-132.
97. Cacoub P, Lunel-Fabiani F, Le Thi Huong D. Polyarteritis nodosa and hepatitis C infection. Annals of Internal Medicine. 116:1992;605-606.
98. Dény P, Bonacorsi S, Guillevin L, Quint L. Association between hepatitis C virus and polyarteritis nodosa. Clinical and Experimental Rheumatology. 10:1992;319-324.
99. Carson C W, Conn D L, Czaja A J, Wright T L, Brecher M E. Frequency and significance of antibodies to hepatitis C virus in polyarteritis nodosa. Journal of Rheumatology. 20:1993;304-309.
100. Ferri C, La Civita L, Caracciolo F, Zignego A L. Non-Hodgkin's lymphoma: possible role of hepatitis C virus. Journal of the American Medical Association. 272:1994;355-356.
101. Ferri C, Caracciolo F, Zignego A L. Hepatitis C virus infection in patients with non-Hodgkin's lymphoma. British Journal of Haematology. 88:1994;392-394.
102. Mazzaro C, Zagonel V, Monfardini S. Hepatitis C virus and non-Hodgkin's lymphomas. British Journal of Haematology. 94:1996;544-550.
103. Zuckerman E, Zuckerman T, Levine A M. Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma. Annals of Internal Medicine. 127:1997;423-428.
104. McColl M D, Singer I O, Tait R C. The role of hepatitis C virus in the aetiology of non-Hodgkin's lymphoma - a regional association? Leukemia and Lymphoma. 26:1997;127-130.
105. Hausfater P, Cacoub P, Bernard N. Hepatitis C virus infection and malignant lymphoproliferative disease: French national study. Arthritis and Rheumatism. 41:1998;S307.
106. Germanidis G, Haioun C, Pourquier J. Hepatitis C virus infection in patients with overt B-cell non-Hodgkin's lymphoma in a French center. Blood. 33:1999;1778-1779.
107. Ferri C, La Civita L, Monti M. Can type C hepatitis infection be complicated by malignant lymphoma? Lancet. 346:1995;1426-1427.
108. Agnello V, Chung R T, Kaphan L M. A role for hepatitis C virus infection in type II cryoglobulinemia. New England Journal of Medicine. 327:1992;1490-1495.
109. Wong V S, Egner W, Elsey T, Brown D, Alexander G J. Incidence, character and clinical relevance of mixed cryoglobulinaemia in patients with chronic hepatitis C virus infection. Clinical and Experimental Immunology. 104:1996;25-31.
110. Zignego A L, Ferri C, Giannini C. Hepatitis C virus genotype analysis in patients with types II mixed cryoglobulinemia. Annals of Internal Medicine. 124:1996;31-34.
111. Frangeul L, Musset L, Cresta P. Hepatitis C virus genotypes and subtypes in patients with hepatitis C, with and without cryoglobulinemia. Journal of Hepatology. 25:1996;427-432.
112. Willems M, Sheng L, Roskams T. Hepatitis C virus and its genotypes in patients suffering from chronic hepatitis C with or without a cryoglobulinemia-related syndrome. Journal of Medical Virology. 44:1994;266-271.
113. Lunel F, Musset L, Cacoub P. Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage. Gastroenterology. 106:1994;1291-1300.
114. Fayyazi A, Schott P, Hartmann H. Clinical, biochemical, and histological changes in hepatitis C virus infection-associated cryoglobulinemia. Gastroenterology. 35:1997;921-928.
115. Monti G, Galli M, Invernizzi F. Cryoglobulinemias: a multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. Quarterly Journal of Medicine. 88:1995;115-126.
116. Abuaf N, Lunel F, Giral P. Non-organ specific autoantibodies associated with chronic C virus hepatitis. Journal of Hepatology. 18:1993;359-364.
117. Cacoub P, Renou P, Cohen P. Extrahepatic manifestations of hepatitis C virus infection: a French prospective multicenter study with multivariate analysis in 298 patients. Arthritis and Rheumatism. 40:1997;S9.
118. Borotto E, Lunel F, Valla D. Prévalence et signification des anticorps anti-organites non spécifiques du foie au cours des hépatites chroniques virales C. Gastroenterologie Clinique et Biologique. 18:1994;813-818.
119. Cacoub P, Musset L, Hausfater P. No evidence for abnormal immune activation in peripheral blood T cells in patients with hepatitis C virus infection (HCV) with or without cryoglobulinemia. Clinical and Experimental Immunology. 113:1998;48-54.
120. Cacoub P, Musset L, Amoura Z. Anti-cardiolipin, anti-β2 glycoprotein 1, and antinucleosome antibodies in hepatitis C virus infection with or without mixed cryoglobulinemia. Journal of Rheumatology. 24:1997;2139-2144.
121. Tran A, Quaranta J F, Benzaken S. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology. 18:1993;253-257.
122. Marcellin P, Pouteau M, Benhamou J P. Hepatitis C virus infection, alpha interferon therapy and thyroid dysfunction. Journal of Hepatology. 22:1995;364-369.
123. Doullay F, Ruf J, Codaccioni J L, Carrayon P. Prevalence of autoantibodies to thyroperoxydase in patients with various thyroid and autoimmune disease. Autoimmunity. 9:1991;237-244.
124. Freidman S L. Cellular networks in hepatic fibrosis. Digestion. 59:1998;368-371.